REFRACTORY LYMPHOMA
Clinical trials for REFRACTORY LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) for people with mantle cell lymphoma, a type of blood cancer. It includes patients whose cancer has come back after treatment and those who have not yet been treated. The main goals a…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Austin I Kim • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug duo targets Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing the safety and effectiveness of a new two-drug combination for people with advanced solid tumors, including pancreatic cancer, that have spread or stopped responding to standard treatments. The trial aims to find the best dose and see if the drugs can help c…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for kids with aggressive brain tumors: experimental drug trial opens
Disease control Recruiting nowThis early-stage trial is testing a new drug called CBL0137 in children and young adults (ages 1-21) whose solid tumors, brain tumors, or lymphoma have come back or stopped responding to standard treatments. The main goals are to find the safest dose and see if the drug can help …
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New weapon tested against Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing a new type of CAR-T cell therapy called LMY-920 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to standard treatments. The therapy uses the patient's own modified imm…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New 'Living Drug' trial offers hope for patients with Tough-to-Treat lymphoma
Disease control Recruiting nowThis is an early-stage study testing a new type of personalized cell therapy called GB5005 in adults with a specific type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard treatments. The main goal is to check the safety and side effects of…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Mega-Dose vitamin c joins fight against stubborn blood cancers
Disease control Recruiting nowThis study is testing if adding high-dose vitamin C (given through an IV) to standard chemotherapy can help patients whose lymphoma has returned or hasn't responded to treatment. It also tests vitamin C alone for certain pre-leukemia conditions. The goal is to see if vitamin C ma…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New drug cocktail aims to wipe out stubborn lymphoma
Disease control Recruiting nowThis study is testing whether a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—is safe and effective for people whose follicular or marginal zone lymphoma has come back or hasn't responded to prior treatments. About 45 participants will receive the treatment …
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE2 • Sponsor: Reid Merryman, MD • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC